Navigation Links
New medical weapons to protect against anthrax attacks

The 2001 anthrax attacks in the United States are fostering development of a new generation of vaccines, antibiotics, and other medications to protect people against the potentially deadly bacteria in any future bioterrorist incident. That's the conclusion of a sweeping overview of scientific research on medical technology to combat the anthrax threat. It appears in ACS' bi-weekly Journal of Medicinal Chemistry.

In the article, Dimitrios Bouzianas notes that several existing antibiotics are available to combat an anthrax infection. However, the emergence of artificially engineered B. anthracis strains, resistant to multiple antibiotics (including the front-line agents ciprofloxacin, doxycycline, and β-lactam antibiotics) has prompted researchers to pursue additional therapeutic options. Such alternatives include small molecules and antibodies against toxins that the lethal bacteria secrete. Passive immunization using a polyclonal or a high-affinity monoclonal antibody may offer adjunctive value to antibiotic therapy. Today's drug arsenal has another weakness: no medications available to fight the dangerous toxin that can circulate in a person's blood when antibiotic treatment begins after the disease has taken hold. Therefore, there is an urgent need for the discovery of antitoxin agents that would be effective at the end stage of anthrax.

Bouzianas describes promising new treatments now in various stages of development. They include a new genre of anthrax vaccines that would be more effective and yet require fewer doses than current vaccines. Among them: A long-sought inhalable vaccine that people might self-administer without a needle. Importantly, this powered vaccine would not require refrigeration and would have a long shelf life ideal for the strategic drug stockpiles kept on hand for rapid distribution in case of national emergencies. Also on the horizon: New antibiotics that are less likely to encounter resistance and medicines that can block the effects of anthrax toxin. Because anthrax is rare as a natural disease in humans, the development of new treatment modalities is seriously hampered by the difficulty in demonstrating their effectiveness in humans.


Contact: Michael Bernstein
American Chemical Society

Related biology news :

1. American College of Medical Genetics responds to new FDA labeling decision for warfarin
2. M2SYS Partners With Gnosis Medical Services to Provide Accurate Patient Identification in Developing Countries Through Innovative Biometrics Solution
3. Boston University biomedical engineers find chink in bacterias armor
4. $22 million gift from Alfred Taubman launches new biomedical research institute
5. USC biomedical team to participate in $6 million low vision project
6. 3 Columbia University Medical Center faculty elected to Institute of Medicine
7. Phase 2 of Singapores Biomedical Sciences Initiative gains momentum for clinical research
8. UMass Medical School researchers receive $8.5M grant award to fight AIDS
9. Natural product discovery by Cleveland medical researchers blocks tissue destruction
10. Triage study challenges notions of emergency medical response to disaster
11. Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network
Post Your Comments:
Related Image:
New medical weapons to protect against anthrax attacks
(Date:11/16/2015)... Nov 16, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced expansion of its TDDI product ... touch controller and display driver integration (TDDI) solutions ... These new TDDI products add to the previously-announced ... TD4302 (WQHD resolution), and TD4322 (FHD resolution) solutions. ...
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/2/2015)... Nov. 2, 2015  SRI International has been awarded ... preclinical development services to the National Cancer Institute (NCI) ... provide scientific expertise, modern testing and support facilities, and ... pharmacology and toxicology studies to evaluate potential cancer prevention ... The PREVENT Cancer Drug Development Program is an NCI-supported ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... , ... November 24, 2015 , ... ... of the year and one of the premier annual events for pharmaceutical manufacturing: ... from 8–11 November 2015, where ISPE hosted the largest number of attendees in ...
(Date:11/24/2015)... India , November 24, 2015 ... a new market research report "Oligonucleotide Synthesis Market by ... Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, ... 2020", published by MarketsandMarkets, the market is expected to ... Million in 2015, at a CAGR of 10.1% during ...
(Date:11/24/2015)... 24, 2015 SHPG ) announced today that ... Piper Jaffray 27 th Annual Healthcare Conference in ... at 8:30 a.m. EST (1:30 p.m. GMT). --> SHPG ... will participate in the Piper Jaffray 27 th Annual Healthcare ... Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ...
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ ... (the "Company") announced today that the remaining 11,000 ... Common Share Purchase Warrants (the "Series B Warrants") ... agreement were exercised on November 23, 2015, which ... Common Shares.  After giving effect to the issuance ...
Breaking Biology Technology: